Cancer Report 2023
€2,200 amount
About the report
Published November 2023. Recognising that the field remains highly immature, this extensive report explores some of the potential implications of the emerging area of microbiome science in the context of oncology, and what this could mean for the makers of pre- pro- and postbiotics products. This report is intended for educational purpose only, the objective is to show the state of the art in the cancer and the microbiome research and market development domain.
This report is next in the series of ‘Uncovering white spaces for biotics’ and should be read by those in the probiotic, nutra and pharma space with an interest in this emerging field.
Regulatory assessment is not a part of the scope of this report. As such, claims made on reviewed products have not been assessed for regulatory compliance. As the regulatory framework has not been clarified, freedom to operate, or lack of it, needs to be assessed individually and incorporated into any project timelines.
What this report tells you
- Which lines of microbiome research are currently being pursued by prominent cancer NGOs and biotech/pharma companies
- The potential of microbiota precision medicine to reshape current approach to cancer prevention, early diagnosis, treatment and recovery
- The potential of biotics in the patient-centric chemo and radio therapy
- Scan of relevant scientific studies published in the last three years carried out on pro/pre/postbiotics
- What types of biotic supplements are currently on the market espousing cancer-related claims, what kinds of claims these are.
- NGOs & Biotech pour resources into cancer & microbiome research.
- Research Insights: Microbiota precision medicine
- Research Insights: The butyrate connection
- Research Insights: Biotics during radio and chemotherapy
- E-commerce Marketplace
- Product Focus: Which products make what cancer-related claims?
- Outlook
About the author
Ewa Hudson
Director of Insights Lumina Intelligence
With 20+ years experience in tracking health and wellness, microbiome and e-commerce trends, Ewa offers a unique perspective and expertise on the marketplace and its growth opportunities. She oversees the research and content strategy for Lumina Intelligence, a business intelligence service from William Reed. In her previous role, Ewa managed the global Health and Wellness, Nutrition and Ethical Labels industries at Euromonitor International. She has a master’s degree in economics from the university of Poznan, Poland and a postgraduate Marketing studies at the University of Westminster in London.